Literature DB >> 22348556

The cutaneous manifestations of metastatic malignant melanoma.

Kurtis B Reed1, Robert H Cook-Norris, Jerry D Brewer.   

Abstract

Cutaneous metastases are common sequelae of primary malignant melanoma. Because patients with melanoma are examined frequently after diagnosis, it is important that dermatologists are aware of the range of findings that may represent metastatic disease. Many case reports and a few retrospective series have been published detailing the wide variety of clinical presentations of cutaneous metastatic melanoma. This article reviews the various manifestations of metastatic melanoma of the skin and oral mucous membranes and summarizes treatment options for metastatic disease.
© 2012 The International Society of Dermatology.

Entities:  

Mesh:

Year:  2012        PMID: 22348556     DOI: 10.1111/j.1365-4632.2011.05245.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  4 in total

Review 1.  Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective.

Authors:  Nigel Fleeman; Adrian Bagust; Sophie Beale; Angela Boland; Rumona Dickson; Kerry Dwan; Marty Richardson; Yenal Dundar; Helen Davis; Lindsay Banks
Journal:  Pharmacoeconomics       Date:  2015-09       Impact factor: 4.981

2.  Do Not Judge a Book by its Cover: Masquerading as Keratoacanthoma.

Authors:  Aleksandra A Stefaniak; Iwona Chlebicka; Piotr Krajewski; Zdzisław Woźniak; Jacek C Szepietowski
Journal:  Acta Derm Venereol       Date:  2020-03-12       Impact factor: 3.875

3.  Widespread finger skin metastases of melanoma.

Authors:  Faruk Tas; Kayhan Erturk
Journal:  Clin Case Rep       Date:  2018-01-15

4.  Multiple disseminated keratoacanthoma-like nodules: a rare form of distant metastases to the skin.

Authors:  Alina Jankowska-Konsur; Karolina Kopeć-Pytlarz; Zdzisław Woźniak; Anita Hryncewicz-Gwóźdź; Joanna Maj
Journal:  Postepy Dermatol Alergol       Date:  2018-07-19       Impact factor: 1.837

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.